Common incretin-related effects discussed in the broader GLP-1 and metabolic drug class may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, or abdominal discomfort, but trial observations do not establish safe personal use of a research peptide
The following is a research schedule , not a prescription
It can be administered as a topical cream, spray, injection, or oral supplement
If you're considering a switch, discussing your genetic predisposition context with your provideralongside your current treatment outcomes and the real financial or access barriers driving the decisioncreates a more complete clinical picture
But as people working in the tobacco industry can testify, being the subject of widespread disrepute is more than offset by the nancial rewards
We still don't know about long-term developmental impacts and the researchers themselves called for more studies on this topic